In this podcast episode, breast cancer experts Manali Bhave, MD, and Erin F. Cobain, MD, discuss their management of patients with HR-positive/HER2-negative early breast cancer including insights on identifying high-risk disease considering clinical/pathological factors and gene expression assays and answering healthcare professional questions on how to personalize adjuvant therapy for these patients. Supported by an educational grant from Lilly.

Faculty:

Manali Bhave, MD
Medical Director, Phase I Clinical Trials Unit
Assistant Professor
Department of Hematology and Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Erin F. Cobain, MD
Associate Professor of Internal Medicine
Division of Hematology/Oncology
Breast Oncology Program
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan 

Link to obtain CME/CE credit: 
https://bit.ly/46RvtgH

Link to Oncology Breast Cancers with additional educational activities: 
https://bit.ly/4h7R3AO

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, breast cancer experts Manali Bhave, MD, and Erin F. Cobain, MD, discuss their management of patients with HR-positive/HER2-negative metastatic breast cancer including the current treatment algorithm, implementing genomic testing for assessing molecular resistance and guiding treatment decisions, and answering healthcare professional questions on how to personalize therapy for these patients. Supported by an educational grant from Lilly.

Faculty:

Manali Bhave, MD
Medical Director, Phase I Clinical Trials Unit
Assistant Professor
Department of Hematology and Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Erin F. Cobain, MD
Associate Professor of Internal Medicine
Division of Hematology/Oncology
Breast Oncology Program
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan 

Link to obtain CME/CE credit:
https://bit.ly/4nUJO1O

Link to Oncology Breast Cancers with additional educational activities:
https://bit.ly/4nNGlBY

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss new and emerging therapies for the personalized care of patients with HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancer (BTC), including:

• Brief overview of BTC and GEA
• Approved HER2-directed therapies for BTC and GEA and their mechanisms of action
• Efficacy and toxicities of the approved agents and optimal management strategies
• Key ongoing trials of HER2-directed therapies in BTC and GEA
• Challenges faced by healthcare professionals in the management of patients with BTC and/or GEA 

Presenters

Amit Mahipal, MD, MPH
Director, Gastrointestinal Medical Oncology Program
Ruth and Donald Goodman Endowed Chair in GI Oncology
Professor of Medicine, Senior Attending Physician
University Hospitals Siedman Cancer Center
Case Comprehensive Cancer Center
Case Western Reserve University
Cleveland, Ohio

Shubham Pant, MD
Professor
Department of Gastrointestinal (GI) Medical Oncology
Department of Investigational Cancer Therapeutics
Director of Clinical Research
Associate Director for Early Phase Drug Development
Sheikh Ahmed Bin Zayed Al Nahyan Center
MD Anderson Cancer Center
Houston, Texas

Link to full program:
https://bit.ly/3KL2ank

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dr Christopher Flowers and Dr John Allan discuss their experience with the use of CD20xCD3 bispecific antibodies in the treatment of patients with relapsed/refractory follicular lymphoma. They also their thoughts on key ongoing clinical trials with bispecific antibodies that they are excited about for their potential to change the standard of care for patients with follicular lymphoma. The overall discussion between these 2 experts includes:

• Using bispecific antibodies in clinical practice for relapsed/refractory follicular lymphoma, including an overview of the drugs mosunetuzumab, epcoritamab, and odronextamab
• Monitoring and managing CRS and ICANS when prescribing bispecific antibodies to patients with relapsed/refractory follicular lymphoma 
• Promising ongoing clinical trials with bispecific antibodies for patients with follicular lymphoma, such as EPCORE FL-1 with epcoritamab, OLYMPIA-5 with odronextamab, and SOUNDTRACK-F1 with surovatamig

Presenters: 

Dr Christopher Flowers 
Division Head, Division of Cancer Medicine
Chair, Professor, Department of Lymphoma/Myeloma
John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine
MD Anderson Cancer Center
Houston, Texas

Dr John Allan
Associate Professor of Clinical Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York

Content based on an online CME program supported by Regeneron Pharmaceuticals, Inc.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen in as Zev A. Wainberg, MD; Paul E. Oberstein, MD; and Mark O’Hara, MD, discuss the evolving treatment landscape for metastatic pancreatic cancer, including:

• How patients often present with disease-related symptoms
• Treatment selection considerations for the first-line and second-line setting
• How to approach palliative care discussions with patients
• Emerging therapies that are showing promise in this setting

Presenters

Paul E. Oberstein, MD
Associate Professor of Medicine
Section Chief, GI Oncology
Perlmutter Cancer Center
NYU Langone Health
New York, New York

Mark O’Hara, MD
Associate Professor of Medicine
Division of Hematology and Oncology
University of Pennsylvania
Philadelphia, Pennsylvania

Zev A. Wainberg, MD
Professor of Medicine and Surgery
Co-Director of GI Oncology
Director, Early Phase Clinical Research Program
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Link to full program: 
https://bit.ly/45NdBTx

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dr Brad Kahl and Dr Noopur Raje discuss the recent advances and emerging data for CAR T-cell therapy in lymphomas and multiple myeloma including the latest evidence from long-term clinical trial follow-up and real-world data, plus new data with CAR T-cell therapies in new lymphoma settings and novel CAR T-cell therapies currently under development for multiple myeloma.

• Lymphomas
  • DLBCL: Real-world outcomes post axi-cel, CAR T vs autologous HSCT
  • FL: Tisa-cel (ELARA), axi-cel (ZUMA-5)
  • MZL: Liso-cel (TRANSCEND FL)
  • MCL: Real-world outcomes post brexu-cel
  • CLL: Liso-cel (TRANSCEND CLL 004)
• Multiple Myeloma
  • Cilta-cel (CARTITUDE-1)
  • Anito-cel (iMMagine-1)
  • GC012F
  • Arlo-cel
  • BMS-986453
  • TriPRIL
     

Presenters:

Brad Kahl, MD
Professor of Medicine
Washington University 
St Louis, Missouri

Noopur Raje, MD 
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
 

Content based on an online CME program supported by an independent educational grant from Bristol Myers Squibb.

Link to full program: 
https://bit.ly/3ViR62V

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Drs William J. Gradishar, Heather McArthur, and Joanne Mortimer address audience questions from a recent live event on the use of CDK4/6 inhibitors in patients with early and metastatic breast cancer, including:

• Genomic testing options for assessing risk of recurrence
• Adjuvant treatment duration and holidays with CDK4/6 inhibitors
• Managing renal toxicities, prophylaxis for DVT, and asymptomatic ILD
• CDK4/6 inhibitors with inavolisib and fulvestrant

Presenters:
William J. Gradishar, MD, FACP, FASCO
Betsy Bramsen Professor of Breast Oncology
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois

Heather McArthur, MD, MPH, FASCO
Professor, Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

Joanne Mortimer, MD, FACP, FASCO
Vice Chair, Medical Oncology
Professor, Division of Medical Oncology & Experimental Therapeutics
Associate Director for Education and Training
Baum Family Professor of Women’s Cancers
City of Hope Comprehensive Cancer Center
Duarte, California

Link to full program:
https://bit.ly/4osHLTm

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dr. Daniel Morgensztern and Dr. Jonathan Strosberg discuss the emerging role of DLL3-targeted agents in the management of extrapulmonary neuroendocrine carcinomas, including:

• The clinical implications of using DLL3 as a therapeutic target
• The impact of emerging DLL3-targeted therapies on evolving treatment paradigms
• How to incorporate DLL3-based treatments into clinical practice

Presenters:

Daniel Morgensztern, MD
Professor of Medicine
Clinical Director of Thoracic Oncology
Washington University School of Medicine
St Louis, Missouri

Jonathan Strosberg, MD
Professor
Department of GI Oncology
Moffitt Cancer Center and Research Institute
Tampa, Florida

Content based on an online CME program supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Link to full program: 
https://bit.ly/4mjNPfy

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, listen to Kelly Romo, PharmD, BCOP; and Shauna Kraft, PharmD, BCOP, share their takeaways from a live webinar on available emerging subcutaneous immunotherapy options for patients with cancer including:

• Basic mechanism of action and role of hyaluronidase in subcutaneous immunotherapy formulation and available dosing/schedules
• Available pharmacodynamics/pharmacokinetics, efficacy, and safety data for subcutaneous immunotherapy formulations
• Current and potential models for administration of subcutaneous immunotherapy in the inpatient setting and day-to-day considerations

Presenters:

Kelly Romo, PharmD, BCOP
Manager, Oncology Medical Drug Management and Customer Initiatives
Blue Cross Blue Shield Michigan
Detroit, Michigan

Shawna Kraft, PharmD, BCOP
Clinical Pharmacist, Specialist
Michigan Medicine, Rogel Cancer Center
Clinical Associate Professor
University of Michigan College of Pharmacy
Ann Arbor, Michigan

Resources:
Consolidate your learning with a recording from an on-demand webcast, download the slides associated with this discussion, or read an expert text module or commentary on this topic. 

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, explore the current and future implications of some of their top choices of studies in lymphomas and ALL presented at the EHA and ICML 2025 meetings.

Program Abstracts: 

• POLARGO: Rituximab, Gemcitabine and Oxaliplatin ± Polatuzumab Vedotin for R/R DLBCL
• ECHO: Rituximab-Bendamustine ± Acalabrutinib in Untreated High-Risk MCL
• CADANCE-101: BGB-16673 BTK Degrader in R/R CLL/SLL
• InMIND: Tafasitamab, Lenalidomide, Rituximab in R/R FL
• SHR2554: Oral EZH2 Inhibitor in R/R PTCL
• SYRUS: AZD0486 Bispecific Antibody for R/R B-ALL

Presenters:

Max S. Topp, MD
Head of Hematology and Clinical CAR-T Program Lead
Associated Professor
Medinische Klinik und Poliklinkik II
University of Wurzburg
Wurzburg, Germany

Pier Luigi Zinzani, MD, PhD
Professor of Hematology
Alma Mater Studiorum- University of Bologna
Head, “Seràgnoli” Institute of Hematology
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Department of Medical and Surgical Sciences
Bologna University School of Medicine
Bologna, Italy

Link to full program:
https://bit.ly/4obcJPI

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.